The article 3 Key Takeaways from the Gwella Mushrooms Presentation at Psychedelic Capital was originally published on Microdose.
The modern “shroom boom” is an integral part of the current psychedelic renaissance, and many companies are diving deep into this promising field of therapeutics. Among them is the team at Gwella Mushrooms, who aim to curate masterful botanical blends to improve one’s health. With the world of mushroom and plant medicines holding great promise, the team at Gwella is in the right industry to make a beneficial impact on healthcare. Here are three key takeaways from their June 2021 Psychedelic Capital presentation.
Key Takeaway #1: Gwella is Developing a Diverse Line of OTC Mushroom Products
While many companies in the “shroom boom” are focusing on psychedelic mushrooms, the Gwella team is developing a diverse line of over-the-counter mushroom products. To quote one of their co-founders, Peter Reitano, Gwella’s goal is to help people “optimize, elevate and improve” the betterment of the world. Not only are they aiming to help people with illnesses, but also those who are relatively well and outside the medical framework with their OTC product line. Gwella hopes to help people use these substances safely and effectively. As discussed by their leadership team, using these medicines for personal growth and enriching one’s life is how these substances were used, to begin with.
Key Takeaway #2: Gwella Aims to Build Long-Term Relationships With Their Customers
The team at Gwella has taken the time to truly understand their customers and their needs in the modern age. Gwella co-founder, Peter Reitano, discussed a recent study out of London that showed one in five people were microdosing during the lockdown and the value of extrapolating out that data. Reitano went on to describe how “an enormous amount of people are getting value from these substances outside the medical framework. By helping their customer base use these products responsibly and intentionally “in the now” as Reitano put it, they are genuinely establishing long-term relationships with their customers. Additionally, they are building pre-and post-trip support products as well as other ancillary products to support psychedelic journeys. It is in these ways the Gwella team is connecting with the mushroom-loving community at large.
Key Takeaway #3: Gwella Understands How to Maneuver the Regulatory Landscape
While psilocybin is a focus of the Gwella team (they are a mushroom company after all), they are also making significant efforts to enter the space legally as well. Indeed, Reitano describes how the regulatory landscape doesn’t need to shift for them to be profitable. From providing educational content to CPG (consumer packaged goods) bridge products and more, the Gwella team has several product offerings that do not touch psychedelics themselves. This puts them in a unique position to generate revenue from this nascent space right out the gate instead of waiting for the legal landscape around these drugs to shift. This is an important takeaway from their presentation and key point investors are interested in when looking at Gwella.
A Look Ahead for Gwella Mushrooms
The Gwella team has a robust understanding of the rapidly emerging mushroom therapeutics sector. From building long-term relationships with their customers to advancing a new line of OTC mushroom products for people outside the medical framework, the Gwella team is ready to bring new hope to the world through their robust product line. By closing their presentation with an important discussion about safety, the Gwella team represents all the important qualities of a successful psychedelic business. Investors are sure to keep their eye on the Gwella team and we over at Microdose look forward to observing their continued progress.psilocybin mushroom psychedelic therapeutics microdosing psychedelics investors otc psychedelic capital gwella regulatory landscape